Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Bluejay Diagnostics (NASDAQ: BJDX) provided a corporate update outlining 2026 priorities: complete the SYMON™ II IL-6 clinical study, advance FDA regulatory submission planning, and scale manufacturing and supply chain readiness for its Symphony platform.

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) provided a corporate update outlining 2026 priorities: complete the SYMON™ II IL-6 clinical study, advance FDA regulatory submission planning, and scale manufacturing and supply chain readiness for its Symphony platform. The company reported approximately $5.2M cash, $6.0M stockholders' equity, ~972,000 common shares outstanding, and a $6.8M net loss for FY2025. Bluejay completed a $3.8M warrant-inducement financing and a $4.5M PIPE in 2025, converted prefunded warrants without incremental dilution, and expects to raise at least $20M through end of 2027 to support commercialization and operations.

Positive

• Scale-up progress reduced historical supply-chain risk
• Completed $3.8M warrant-inducement financing and $4.5M PIPE in 2025
• Prefunded warrant exercises converted to shares without extra dilution

Negative

• Cash balance of approximately $5.2M as of Dec 31, 2025
• Net loss of approximately $6.8M for fiscal year 2025
• Company expects to raise at least $20M through end of 2027

Argus Mar 6 session

-2.11% close to close Open Argus

Details

News Market Reaction – BJDX

On Mar 6, the day this news came out, BJDX closed 2.11% below the previous close.

Data tracked by StockTitan Argus for the Mar 6 session.

Key Figures

Shares outstanding: 972,000 shares Cash and equivalents: $5.2 million Stockholders’ equity: $6.0 million +5 more

Shares outstanding

972,000 shares

Common stock outstanding after prefunded warrant exercises

Cash and equivalents

$5.2 million

Expected balance as of Dec 31, 2025

Stockholders’ equity

$6.0 million

Expected as of Dec 31, 2025

Warrant-inducement financing

$3.8 million

Completed in April 2025

PIPE financing

$4.5 million

Completed in October 2025

Net loss

$6.8 million

Fiscal year ended Dec 31, 2025

Additional capital need

At least $20 million

Expected funding need through end of 2027 fiscal year

IL-6 test time

Approximately 20 minutes

Sample-to-result time for IL-6 sepsis test

Historical Context

5 past events · Latest: Feb 20

5 events

1. Feb 20

   Warrant exercises update

   24h Move

   +1.5%

   All prefunded warrants exercised, leaving about 972,000 common shares outstanding.

2. Feb 17

   Clinical/manufacturing update

   24h Move

   +0.8%

   SYMON II enrollment at 545 of 750 patients and manufacturing readiness advances.

3. Jan 27

   Reverse stock split

   24h Move

   -3.9%

   1-for-4 reverse split reducing outstanding shares and adjusting warrants and awards.

4. Dec 29

   Antibody production milestone

   24h Move

   -3.0%

   Completion of commercial-scale IL-6 antibody production for Symphony cartridges.

5. Nov 10

   Corporate/financing update

   24h Move

   +0.0%

   Q3 2025 update, trial progress, and PIPE plus warrant-inducement financings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

interleukin-6 (il-6), sepsis, prefunded warrants, pipe financing, +3 more

7 terms

interleukin-6 (il-6) medical

"lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis"

A signaling protein produced by the body that acts like an alarm bell for the immune system, calling cells to respond when there’s infection, injury or inflammation. Investors watch IL-6 because its levels can predict disease severity, serve as a target for drugs and diagnostics, and influence clinical trial results, regulatory decisions and healthcare costs—so changes related to IL-6 can materially affect the value of biotech and pharmaceutical companies.

sepsis medical

"rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care"

Sepsis is a dangerous medical condition in which an infection triggers the body's defenses to damage its own tissues and organs, often leading to organ failure and emergency hospital care. For investors it matters because sepsis drives demand for diagnostics, antibiotics, intensive-care treatments and hospital resources, affects healthcare costs and insurer payouts, and can influence the commercial prospects and valuation of companies developing related tests, drugs and devices.

prefunded warrants financial

"announced the full exercise of previously issued prefunded warrants. These exercises represented"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

pipe financing financial

"warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

regulatory submission regulatory

"positioning the Company for planned regulatory submission and subsequent commercialization"

A regulatory submission is the package of documents, data and forms a company sends to a government agency to request approval for a product, drug, device, or a change in how it is marketed or made. Think of it like applying for a building permit: the agency reviews safety, effectiveness and compliance before giving the green light; for investors, the timing, completeness and outcome of a submission can change a company’s revenue prospects, costs and risk profile.

statistical analysis plan medical

"in accordance with the analysis of primary end points with the study’s statistical analysis plan"

A statistical analysis plan is a detailed written blueprint that explains exactly how study data will be measured, compared and reported, including which outcomes will be examined, which calculations will be used, and how missing or messy data will be handled. For investors it matters because a clear, pre‑set plan reduces the risk of biased or surprising results—think of it as a recipe that ensures reported findings are reproducible and trustworthy for judging a drug or product’s prospects.

u.s. food and drug administration regulatory

"authorization from the U.S. Food and Drug Administration before Symphony can be marketed"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026.

Operational and Clinical Progress
Bluejay continues to advance its Symphony™ platform, including the Company’s lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making.

The Company confirmed that its SYMON™ II clinical study is progressing as planned, with ongoing site activities and enrollment consistent with internal timelines. Data generated from this study is intended to support the Company’s regulatory strategy. Due to regulatory considerations, including FDA requirements and disclosure constraints, Bluejay may be limited in its ability to release detailed clinical data prior to regulatory submission; however, the Company intends to provide appropriate updates in accordance with the analysis of primary end points with the study’s statistical analysis plan.

Manufacturing and Commercial Readiness
Bluejay continues to execute its manufacturing readiness strategy, including scale-up activities designed to support both clinical and future commercial production. Key supply-chain initiatives and process validation efforts remain on track, positioning the Company for planned regulatory submission and subsequent commercialization readiness.

The Company has achieved meaningful progress in critical raw materials, antibody supply, cartridge manufacturing preparation, and external manufacturing coordination, which collectively reduce historical supply-chain risk and support long-term scalability.

Corporate and Capital Structure Update
During February 2026, the Company announced the full exercise of previously issued prefunded warrants. These exercises represented the conversion of existing instruments into common shares and did not create incremental dilution beyond the Company’s previously disclosed fully diluted share structure.

Following these exercises, the Company has approximately 972,000 shares of common stock outstanding, in addition to outstanding cash-exercisable warrants with strike prices above current trading levels.

The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.

2026 Strategic Priorities
Through 2026, Bluejay’s primary strategic focus areas include:

• Completion and execution of the SYMON™ II study and advancement toward regulatory submission
• Continued manufacturing scale-up and operational readiness for commercialization
• Strengthening supply-chain robustness and production capacity
• Advancement of Symphony™ platform capabilities
• Ongoing engagement with investors, scientific conferences, and strategic partners
• Raising additional capital as part of the Company’s expectation that it will need to raise at least $20 million of further capital through the end of the 2027 fiscal year, which it hopes to do in various tranches

The Company expects to provide updates through press releases, conference participation, and other investor communications as milestones are achieved or material developments occur

Management Commentary
“Bluejay continues to execute against its core clinical, operational, and regulatory priorities,” said Neil Dey, Chief Executive Officer of Bluejay Diagnostics. “Our focus through 2026 remains disciplined — advancing clinical validation, preparing manufacturing for commercialization, and positioning the Symphony platform to deliver meaningful value for patients, clinicians, and shareholders.”

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310

Website: www.bluejaydx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the status of Bluejay Diagnostics' SYMON™ II study and timeline (BJDX)?

The SYMON II study is progressing on schedule with ongoing site activity and enrollment. According to Bluejay Diagnostics, data will support regulatory strategy and updates will follow analysis of primary endpoints per the study's statistical analysis plan.

How much cash and equity did Bluejay Diagnostics report as of December 31, 2025 (BJDX)?

Bluejay reported about $5.2 million in cash and $6.0 million in stockholders' equity. According to Bluejay Diagnostics, those figures reflect post-2025 financings including a $3.8M warrant-inducement and a $4.5M PIPE in 2025.

How many shares does Bluejay Diagnostics have outstanding after recent warrant exercises (BJDX)?

Following prefunded warrant exercises, Bluejay has approximately 972,000 common shares outstanding. According to Bluejay Diagnostics, the conversions did not create incremental dilution beyond its previously disclosed fully diluted structure.

What are Bluejay Diagnostics' 2026 strategic priorities and commercialization readiness (BJDX)?

Primary 2026 priorities are completing SYMON II, pursuing regulatory submission, and scaling manufacturing readiness. According to Bluejay Diagnostics, efforts include supply-chain robustness, cartridge manufacturing preparation, and external manufacturing coordination for commercialization.

How much additional capital does Bluejay Diagnostics expect to raise and why (BJDX)?

Bluejay expects to raise at least $20 million through the end of fiscal 2027 to support clinical, manufacturing, and commercialization activities. According to Bluejay Diagnostics, the company plans to raise funds in various tranches as needed.